Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges
Haoyu Tian, Shuairan Zhang, Ying Liu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4583-4583
Open Access | Times Cited: 21

Showing 21 citing articles:

Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance
Alan L. Hutchison, Federica Tavaglione, Stefano Romeo, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 6, pp. 1524-1541
Open Access | Times Cited: 74
Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases
Susana Rodrigues, Van der Merwe, Aleksander Krag, et al.
Seminars in Immunology (2024) Vol. 71, pp. 101859-101859
Open Access | Times Cited: 15
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B. Patel
World Journal of Gastroenterology (2023) Vol. 29, Iss. 32, pp. 4831-4850
Open Access | Times Cited: 19
The natural compounds, Magnolol or Honokiol, promote adipose tissue browning and resist obesity through modulating PPARα/γ activity
Yi Chu, Sisi Gui, Yazhen Zheng, et al.
European Journal of Pharmacology (2024) Vol. 969, pp. 176438-176438
Closed Access | Times Cited: 5
Altered mitochondrial unfolded protein response and FGF21 secretion in MASLD progression and the effect of exercise intervention
Xinmeng Yuan, Wen Sun, Ye Xu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease—Clinical and Pre-Clinical Overview and Systematic Review of the Literature
Florentina Ioniţă‐Radu, Cristina Patoni, Andreea Simona Nancoff, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4201-4201
Open Access | Times Cited: 4
Caffeic acid ameliorates metabolic dysfunction-associated steatotic liver disease via alleviating oxidative damage and lipid accumulation in hepatocytes through activating Nrf2 via targeting Keap1
Jinyu Zhang, Hao Ouyang, Xin-Nan Gu, et al.
Free Radical Biology and Medicine (2024) Vol. 224, pp. 352-365
Closed Access | Times Cited: 4
Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions
Yu Wu, Pu Dong, Q H Wu, et al.
Clinical Pharmacology & Therapeutics (2025)
Closed Access
Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon
Jorge Arnold, Francisco Idalsoaga, Luis Antonio Díaz, et al.
Current Hepatology Reports (2024) Vol. 23, Iss. 1, pp. 204-219
Closed Access | Times Cited: 3
Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Angeliki Katsarou, Georgios Tsioulos, Eva Kassi, et al.
HORMONES (2024) Vol. 23, Iss. 4, pp. 621-636
Closed Access | Times Cited: 3
NASH Drug Development: Seeing the Light at the End of the Tunnel?
Yong Q. Chen
Journal of Clinical and Translational Hepatology (2023) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 7
Potential therapeutic strategies for MASH: from preclinical to clinical development
Zhifu Xie, Yufeng Li, Long Cheng, et al.
Life Metabolism (2024) Vol. 3, Iss. 5
Open Access | Times Cited: 2
FGF19 Promotes the Proliferation and Insulin Secretion from Human Pancreatic β Cells Via the IRS1/GLUT4 Pathway
Ting Zeng, Xi Tang, Xiaosu Bai, et al.
Experimental and Clinical Endocrinology & Diabetes (2024) Vol. 132, Iss. 03, pp. 152-161
Closed Access | Times Cited: 1
Role of serum endotoxin, FGF19, TLR2, TNF-α, IL-12 and IL-10 in NAFLD-associated T2DM pathogenesis: Insights into Th1 bias and protective mechanisms
Snigdha Jyoti Das, Barsha Gadapani Pathak, Sangit Dutta, et al.
Indian Journal of Gastroenterology (2024)
Closed Access | Times Cited: 1
Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy
Shahid Habib
World Journal of Gastrointestinal Pathophysiology (2024) Vol. 15, Iss. 4
Open Access | Times Cited: 1
Efficacy and safety of the FGF19 analog aldafermin for the treatment of nonalcoholic steatohepatitis (NASH): A GRADE assessed systematic review and Meta-Analysis
Mohammad Haris Ali, Obaid Ur Rehman, Muhammad Talha, et al.
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 12, pp. 7072-7081
Open Access | Times Cited: 1
Endogenous FGF1 Deficiency Aggravates Doxorubicin-Induced Hepatotoxicity
Chunjie Gu, Zijuan Liu, Yingjian Li, et al.
Toxics (2023) Vol. 11, Iss. 11, pp. 925-925
Open Access | Times Cited: 2
The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative review
Cristina Elena Negroiu, Robertina Iulia Tudoraşcu, Maria Cristina Beznă, et al.
Romanian Journal of Morphology and Embryology (2024) Vol. 65, Iss. 2, pp. 159-172
Open Access
The Role of Gut Microbiota in Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD)
Săndica Bucurică
IntechOpen eBooks (2024)
Closed Access
NAFLD/MAFLD: New Evidence
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7241-7241
Open Access | Times Cited: 1
Hidden Complication of Obesity and Diabetes: Is It Time to Put More Focus on Fatty Liver?
James Kim, Giada Sebastiani
EMJ Diabetes (2023), pp. 77-84
Open Access
Page 1

Scroll to top